The post-immune checkpoint inhibitor era:hopes and challenges for lung cancer immunotherapy
10.3781/j.issn.1000-7431.2024.2401-0021
- VernacularTitle:后免疫检查点抑制剂时代:肺癌免疫治疗的希望和挑战
- Author:
Manyi XU
1
;
Yue HAO
1
;
Zhengbo SONG
1
Author Information
1. 浙江省肿瘤医院Ⅰ期临床试验病房,中国科学院杭州医学研究所,浙江 杭州 310022
- Publication Type:Journal Article
- Keywords:
Lung cancer;
Immunotherapy;
Agonist;
Bispecific antibody;
Adoptive cellular immunotherapy
- From:
Tumor
2024;44(6):598-620
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is one of the most prevalent and the highest mortality rate malignancies,and its treatment landscape has undergone a disruptive transformation with the discovery and clinical application of immune checkpoint inhibitors.However,there still exists a number of patients who acquire resistance or fail to respond to these treatments,posing new challenges for lung cancer therapy.In light of this,there is an urgent need to actively explore and develop novel targets and innovative therapeutic strategies.This article aims to review the cutting-edge advancements in the novel immune checkpoint inhibitors,agonists,bispecific antibodies,adoptive cellular immunotherapy,and combination therapies involving immune checkpoint inhibitors,as well as to revisit existing related clinical trials along with their limitations,with the goal of advancing lung cancer immunotherapy towards a more personalized and precise approach.
